# Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct07487103` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07487103](<https://clinicaltrials.gov/study/NCT07487103>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07487103

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 478 participants.

## Technical summary

Registry record NCT07487103. Randomized; no masking; primary purpose treatment. Start 2026-05-01 (anticipated); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 478 participants (planned count; ClinicalTrials.gov record NCT07487103, source copy `cardio:ctgov-nct07487103-2026-04-28`, retrieved 2026-10-26)
- Planned start: 2026-05-01 (anticipated) (ClinicalTrials.gov record NCT07487103, source copy `cardio:ctgov-nct07487103-2026-04-28`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07487103, source copy `cardio:ctgov-nct07487103-2026-04-28`, retrieved 2026-10-26)
- Completion: 2027-05 (anticipated) (ClinicalTrials.gov record NCT07487103, source copy `cardio:ctgov-nct07487103-2026-04-28`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07487103-2026-04-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): QLG1091
- Intervention (Drug): Rybelsus
- Lead sponsor: Qilu Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Qilu Pharmaceutical Co., Ltd. (`cardio:org-qilu-pharmaceutical-co-ltd`)

## Provenance

Content hash: 7552ad9c407e7cdf2db0d1f5fc862903f0cfbc0894bfdf944ae8db68dbb11640
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
